Denali Therapeutics Inc. announced that the Sean M. Healey & AMG Center in collaboration with the Northeast ALS Consortium (NEALS) completed enrollment for Regimen G of the Phase 2/3 HEALEY ALS Platform Trial, which evaluates Denali?s eIF2B agonist DNL343. Regimen G is co-led by Suma Babu, MBBS, MPH, and Sabrina Paganoni, MD, PhD, physician investigators at the Healey & AMG Center for ALS at MGH.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
22.51 USD | -2.00% | -0.53% | +4.89% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.89% | 3.28B | |
+16.10% | 122B | |
+18.85% | 113B | |
+18.95% | 26.49B | |
-23.38% | 19.4B | |
-19.03% | 16.24B | |
-19.94% | 15.4B | |
-46.14% | 15.15B | |
+64.83% | 14.93B | |
+5.10% | 13.52B |
- Stock Market
- Equities
- DNLI Stock
- News Denali Therapeutics Inc.
- Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating Eif2b Agonist Dnl343 in the Phase 2/3 Healey ALS Platform Trial